| Darleukin/fibromun | L19-IL-2/ L19-TNF-α | Phase 3 Clinical | Philogen Spa | Basal Cell Nevus Syndrome; Carcinoma, Basal Cell; Carcinoma, Merkel Cell; Carcinoma, Squamous Cell; Melanoma; Sarcoma, Kaposi | 詳細 |
| Bifikafusp alfa | L19-IL-2 | Phase 3 Clinical | Philogen Spa | Adenomatous Polyposis Coli; Carcinoma, Basal Cell; Carcinoma, Non-Small-Cell Lung; Melanoma; Pancreatic Neoplasms; Solid tumours | 詳細 |
| IBI-363 | IBI-363 | Phase 3 Clinical | | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Gastroesophageal Junction Neoplasms; Lymphoma; Melanoma; Mucosal Melanoma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| EQ-101 | EQ101; EQ-101; BNZ132-1-40; BNZ-1; BNZ132-1; BNZ-01 | Phase 2 Clinical | Bioniz Therapeutics Inc | Alopecia; Alopecia Areata; Leukemia, Large Granular Lymphocytic; Lymphoma, T-Cell, Cutaneous | 詳細 |
| umitrelimorgene autodencel | ITI-1000 | Phase 2 Clinical | Immunomic Therapeutics Inc | | 詳細 |
| S-95007 | S-95007 | Phase 2 Clinical | Laboratoires Servier | Immune System Diseases; Inflammation | 詳細 |
| SIM-0278 | ALM-223; SIM0278 | Phase 2 Clinical | Simcere Pharmaceutical Group Ltd | Autoimmune Diseases; Dermatitis, Atopic; Lupus Erythematosus, Systemic; Lupus Nephritis | 詳細 |
| Imneskibart | BD-8; AU-007; BDG-8 | Phase 2 Clinical | Biolojic Design Inc | Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Neoplasms; Skin Melanoma; Solid tumours | 詳細 |
| XTX-202 | XTX-202 | Phase 2 Clinical | Xilio Development Inc, Xilio Therapeutics Inc | Carcinoma, Renal Cell; Melanoma; Solid tumours | 詳細 |
| STK-012 | STK-012 | Phase 2 Clinical | Synthekine Inc | Carcinoma, Non-Small-Cell Lung; Solid tumours | 詳細 |
| EGL-001 | EGL-001 | Phase 2 Clinical | Egle Therapeutics | | 詳細 |
| STI-7349 | STI-7349; ILKN421H | Phase 2 Clinical | The Fourth Affiliated Hospital, Zhejiang University School Of Medcine | Carcinoma, Non-Small-Cell Lung; Solid tumours | 詳細 |
| LAT-010 | LAT010; LAT-010 | Phase 2 Clinical | Latticon Antibody Therapeutics Inc | Neoplasm Metastasis; Solid tumours | 詳細 |
| COYA-302 | COYA 302; COYA-302; COYA302 | Phase 2 Clinical | Coya Therapeutics Inc | Amyotrophic Lateral Sclerosis; Frontotemporal Dementia; Parkinson Disease | 詳細 |
| KB-707 | KB707; KB-707 | Phase 2 Clinical | Krystal Biotech Inc | Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Melanoma; Neoplasms; Skin Melanoma; Solid tumours | 詳細 |
| REGN-10597 | REGN-10597 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Carcinoma, Renal Cell; Melanoma; Neoplasms; Solid tumours | 詳細 |
| SAR-444336 | SAR-444336; THOR-809 | Phase 2 Clinical | Sanofi | Colitis, Microscopic; Inflammation | 詳細 |
| COYA-301 | COYA-301 | Phase 2 Clinical | Coya Therapeutics Inc | | 詳細 |
| Saltikva | MDB401B | Phase 2 Clinical | Salspera LLC, Sunshine Lake Pharma | | 詳細 |
| Igrelimogene litadenorepvec | PM-1016; PM1016; TILT-123 | Phase 2 Clinical | Tilt Biotherapeutics Ltd | Carcinoma, Hepatocellular; Fallopian Tube Neoplasms; Lung Neoplasms; Melanoma; Ovarian Neoplasms; Peritoneal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck | 詳細 |
| LMBP2-specific TCR-T cell therapy (TCRCure Biopharma) | | Phase 2 Clinical | Tcrcure Biopharma Ltd | | 詳細 |
| Interleukin-2 gene therapy (St Jude Children's Research Hospital) | | Phase 1 Clinical | National Cancer Institute, St. Jude Children'S Research Hospital | | 詳細 |
| T20K | T-20K | Phase 1 Clinical | Cyxone | | 詳細 |
| ODC-IL2 | ODC-IL-2; ODC-IL2; ODC-1L2 | Phase 1 Clinical | Trutino Biosciences Inc | | 詳細 |
| Etakafusp alfa | AB-248 | Phase 1 Clinical | Asher Biotherapeutics Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Melanoma; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms | 詳細 |
| ASP-1012 | VET2-L2; ASP-1012; ASP1012 | Phase 1 Clinical | KaliVir Immunotherapeutics Inc | | 詳細 |
| TEV-278 | TEV-278; TEV-‘278 | Phase 1 Clinical | Teva Pharmaceutical Industries Ltd | | 詳細 |
| HM-16390 | HM-16390; HM16390 | Phase 1 Clinical | Hanmi Pharmaceutical Co Ltd | | 詳細 |
| IL2 CD25 fusion protein (Bristol-Myers Squibb) | | Phase 1 Clinical | University Of Miami | | 詳細 |
| EGL-003 | EGL-003 | Phase 1 Clinical | Egle Therapeutics | Autoimmune Diseases; Dermatitis, Atopic; Neoplasms | 詳細 |
| KYS-202003-A | KYS-202003-A; KYS202003A | Phase 1 Clinical | Jiangsu Kanion Pharmaceutical Co Ltd | | 詳細 |
| M5A-IL2 Immunocytokine | M5A-ICK | Phase 1 Clinical | City Of Hope National Medical Center, National Cancer Institute | Breast Neoplasms; Colorectal Neoplasms | 詳細 |
| DF-6215 | DF6215; DF-6215 | Phase 1 Clinical | Dragonfly Therapeutics Llc | | 詳細 |
| Dodekin | | Phase 1 Clinical | Philogen Spa | | 詳細 |
| TEV-56278 | TEV-56278 | Phase 1 Clinical | Teva Pharmaceutical Industries Ltd | Melanoma; Neoplasms; Solid tumours | 詳細 |
| AttIL2-T cell therapy | | Phase 1 Clinical | The University Of Texas MD Anderson Cancer Center | Osteosarcoma; Sarcoma; Soft Tissue Neoplasms | 詳細 |
| Autologous tumor-infiltrating lymphocyte cells therapy (Hervor Therapeutics) | HV-101; HV101 | Phase 1 Clinical | Hangzhou Houwu Biomedical Technology Co Ltd, Hervor Therapeutics, Tcrcure Biopharma Ltd | | 詳細 |
| KY-0118 | KY-0118; KY0118 | Phase 1 Clinical | Novatim Immune Therapeutics (Zhejiang) Co Ltd | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Melanoma; Neoplasms; Pancreatic Neoplasms; Solid tumours | 詳細 |
| VIS171 | VIS-171; VIS171 | Phase 1 Clinical | Visterra Inc | Alopecia Areata; Autoimmune Diseases; Glomerulosclerosis, Focal Segmental; Lupus Erythematosus, Systemic | 詳細 |
| MK-1484 | MK-1484; SP-482 | Phase 1 Clinical | Merck & Co Inc, Sutro Biopharma Inc | | 詳細 |
| CUG-252 | CUG-252 | Phase 1 Clinical | Cugene Inc | Autoimmune Diseases; Lupus Erythematosus, Systemic | 詳細 |
| RS-2102 | RS2102 | Phase 1 Clinical | Reistone Biopharma Co Ltd | | 詳細 |
| BNT-153 | BNT-153 | Phase 1 Clinical | Biontech Se | | 詳細 |